{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-144588","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2026-04-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.540831+00:00","generated_at":"2026-05-15T07:01:15.741078+00:00","sec_items":["5.02","7.01","8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Corbus Pharma announces FDA alignment for CRB-701 accelerated path; CMO resigns","bullets":["FDA agreed on registrational study designs for CRB-701 in second-line HNSCC and cervical cancer, with potential accelerated approval using ORR primary endpoint.","Dr. Dominic Smethurst steps down as Chief Medical Officer, effective June 30, 2026.","Updated CRB-701 monotherapy data accepted for presentation at ASCO 2026 (May 29-June 2).","Company expects to report CRB-701 + Keytruda data in first-line HNSCC in Q4 2026; registrational study for HNSCC to start mid-2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-144588","json":"https://secwatch.observer/filing/0001193125-26-144588.json","markdown":"https://secwatch.observer/filing/0001193125-26-144588.md","text":"https://secwatch.observer/filing/0001193125-26-144588.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000119312526144588/0001193125-26-144588-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000119312526144588/crbp-20260401.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:01:15.741078+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}